PubMed Health⌕ Search

Biomedical subjects

F Mesotten

Publications and source records attributed to F Mesotten.

7 recordsLinked to original sources
PubMed1998

Impaired early visual processing in disorganised schizophrenia.

Topographic differences in flash/pattern shift VEP data are evaluated in paranoid (n: 38), disorganized (n: 23) and residual (n: 23) schizophrenic subtypes and compared to normal controls. Increased early P1 and a restricted diffusion of the late P2 responses suggest dopaminergic over- and cholinergic underactivity in paranoid and residual schizophrenia. A distinctive pattern N145 reflects well-preserved attentional resources in the paranoid subtype. Latency increase and amplitude decrease of the pattern N145 concur with abnormal antisaccades documented in disorganized behaviour. VEP-data might help differentiate between schizophrenic subtypes.

Adult↗
PubMed1997

Auditory information processing in schizophrenia.

Early N1P2 and late N2P3 responses generated in an auditory oddball paradigm are topographically compared in three psychiatric patient groups. In schizophrenia N1 and N2 amplitude is comparable with dementia and significantly decreased with respect to affective disorder. In contrast, P3 amplitude does not allow discriminating schizophrenia from affective disorder but is significantly diminished in dementia. The late N2P3 response shows a topographic effect along the fronto-occipital axis. Schizophrenia is characterized by an iCNV and N2 maximum over the frontal planes and a compound P3 lacking distinct frontal and parietal components. The findings are discussed in reference to literature data and current hypotheses/theories concerning information processing. Our findings favour an important dysfunction of automatic processing including early selection in schizophrenia.

Adult↗
PubMed1994

Controlled comparison of nefazodone and amitriptyline in major depressive inpatients.

Nefazodone, a phenylpiperazine antidepressant, exhibits novel dual activity on serotonin (5-HT) neurons; it binds to 5-HT2 receptors and inhibits 5-HT reuptake. Flexible doses of nefazodone (100-400 mg/day) and amitriptyline (50-200 mg/day) were compared in 106 major depressive inpatients in a 6-week double-blind study. Results showed significant superiority of amitriptyline over nefazodone on all rating instruments: Montgomery and Asberg depression rating scale (P < 0.0001), Hamilton depression scale (P < 0.0006), Clinical Global Impressions (P < 0.0001) and Patient Global Assessment (P < 0.01). A total of 65% of patients under amitriptyline and 56% of patients under nefazodone reported adverse events during the study, with significantly more dry mouth in the amitriptyline group (39% versus 11%, P = 0.001). Modal daily doses within the last treatment week reached 242 mg with nefazodone and 124 mg with amitriptyline. The lower efficacy of nefazodone, which contradicts comparative trials with imipramine in US patients, is discussed with regard to the dose of nefazodone, probably below the optimal therapeutic range for melancholic patients, and to the clinical differences between the patient samples.

Adolescent↗
PubMed1994

Night terrors.

Explore the source record for details and available documents.

Arousal↗
PubMed1989

Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.

Risperidone (R 64766) was administered during 4 weeks in increasing doses to 17 psychotic patients, to evaluate the hematological and cardiovascular safety, the therapeutic effect, side effects, effects upon endocrinological parameters and the pharmacokinetic profile. Following a placebo wash-out period of 1 week, the initial dose was 10 mg daily, increasing with 5 mg per week until the maximal dose of 25 mg daily was reached during the 4th week of treatment. Doses up to 20 mg daily resulted in a significant improvement of the total BPRS score and of the different BPRS factor scores; with higher doses, no further clinical benefit was achieved except for the hostility and anxiety-depression factor, while sedation became more prominent. No increase of extrapyramidal symptoms was noticed. Except for the sedation observed with higher doses, risperidone was well tolerated. No clinically relevant effects on cardiovascular and ECG parameters were noticed, and except for a slight increase of aspartate aminotransferase and alanine aminotransferase in one patient, no laboratory abnormalities were observed. Prolactin showed an expected increase, while the other endocrinological parameters revealed no changes. Risperidone had a linear pharmacokinetic profile.

Adult↗
PubMedDate not supplied

A Belgian multicentre study of fluvoxamine in depressive outpatients.

Fluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p less than 0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.

Adult↗